TDNA T. Rowe Price Biotech ETF
Quote as of Nov 02, 2026 21:00 UTC · Quotes are refreshed hourly from the data provider, so during market hours a price can be up to about 1–2 hours old; each quote shows its own timestamp.
| Previous Close | 24.89 | Day Range | 24.36 – 24.78 |
| 52-Week Range | 22.72 – 25.68 | Volume | 1.74K |
| Avg Volume | 2.10K | AUM | $11.2M (Nov 03, 2026) |
| Expense Ratio | 0.55% | Yield (TTM) | — |
| NAV | 24.90 | Premium/Discount | -2.19% indicative |
| Inception | Sep 16, 2026 | Holdings | 89 |
| Issuer | T. Rowe | Exchange | NASDAQ |
| Category | Biotech | Index Tracked | Not stated in source data |
| CUSIP | 87283Q610 | ISIN | US87283Q6109 |
| Management | Actively managed (per issuer description) | ||
About this ETF
T. Rowe Price Biotech ETF is an actively managed exchange-traded fund that seeks long-term capital appreciation by investing primarily in biotechnology and life sciences companies. The fund focuses on companies developing innovative therapies, medicines, and technologies across areas such as biotechnology, pharmaceuticals, and medical research. T. Rowe Price lists the fund under the ticker TDNA.
Description from the fund data provider · profile as of Nov 03, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | -0.87% | — | — | — | — | — | — | — | -4.45% |
| Total return | -0.85% | — | — | — | — | — | — | — | -4.43% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Nov 02, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.55% | Annual cost of a $10,000 investment | $55.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings list retrieved Oct 31, 2026 · The data provider's latest disclosed portfolio for this fund. Issuers publish holdings daily or monthly, so the portfolio date can be earlier; holdings are not live positions. 89 holdings stored, 25 shown.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | ARGENX SE ADR ADR | ARGX | 5.05% | 637 | $571.9K |
| 2 | KYMERA THERAPEUTICS INC COMMON STOCK USD.0001 | KYMR | 4.42% | 4.08K | $500.6K |
| 3 | KODIAK SCIENCES INC COMMON STOCK USD.0001 | KOD | 2.83% | 3.19K | $320.3K |
| 4 | NATERA INC COMMON STOCK | NTRA | 2.54% | 660 | $287.8K |
| 5 | INSMED INC COMMON STOCK USD.01 | INSM | 2.53% | 2.57K | $286.5K |
| 6 | UNITED THERAPEUTICS CORP COMMON STOCK USD.01 | UTHR | 2.40% | 457 | $271.2K |
| 7 | VERTEX PHARMACEUTICALS INC COMMON STOCK USD.01 | VRTX | 2.32% | 487 | $263.0K |
| 8 | REVOLUTION MEDICINES INC COMMON STOCK | RVMD | 2.20% | 1.31K | $248.7K |
| 9 | MODERNA INC COMMON STOCK USD.0001 | MRNA | 2.20% | 1.12K | $248.6K |
| 10 | VAXCYTE INC COMMON STOCK USD.001 | PCVX | 2.09% | 3.78K | $236.6K |
| 11 | SPYRE THERAPEUTICS INC COMMON STOCK USD.0001 | SYRE | 1.98% | 2.27K | $224.3K |
| 12 | BRIDGEBIO PHARMA INC COMMON STOCK | BBIO | 1.94% | 3.11K | $219.7K |
| 13 | PRAXIS PRECISION MEDICINES I COMMON STOCK… | PRAX | 1.89% | 741 | $213.9K |
| 14 | DIANTHUS THERAPEUTICS INC COMMON STOCK USD.001 | DNTH | 1.79% | 2.45K | $202.9K |
| 15 | RHYTHM PHARMACEUTICALS INC COMMON STOCK | RYTM | 1.77% | 2.15K | $200.0K |
| 16 | CYTOKINETICS INC COMMON STOCK USD.001 | CYTK | 1.75% | 3.14K | $198.6K |
| 17 | ALKERMES PLC COMMON STOCK USD.01 | ALKS | 1.72% | 4.30K | $195.1K |
| 18 | MIRUM PHARMACEUTICALS INC COMMON STOCK | MIRM | 1.66% | 2.17K | $187.6K |
| 19 | RELAY THERAPEUTICS INC COMMON STOCK USD.001 | RLAY | 1.59% | 9.23K | $179.6K |
| 20 | TANGO THERAPEUTICS INC COMMON STOCK USD.0001 | TNGX | 1.56% | 7.82K | $176.1K |
| 21 | ARROWHEAD PHARMACEUTICALS IN COMMON STOCK… | ARWR | 1.55% | 2.89K | $175.0K |
| 22 | CG ONCOLOGY INC COMMON STOCK | CGON | 1.54% | 2.75K | $174.9K |
| 23 | TWIST BIOSCIENCE CORP COMMON STOCK USD.00001 | TWST | 1.54% | 1.00K | $174.0K |
| 24 | SCHOLAR ROCK HOLDING CORP COMMON STOCK USD.001 | SRRK | 1.50% | 3.83K | $169.3K |
| 25 | ERASCA INC COMMON STOCK USD.0001 | ERAS | 1.48% | 11.19K | $167.7K |
Click a ticker to see every ETF that owns it.
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | — | Paid (last 12 months) | — |
| Frequency | — | SEC yield | Not provided by our data source; see the issuer page |
| Last ex-date | — | Last payment | — |
| Growth 1Y | — | Growth 3Y / 5Y (ann.) | — / — |
No distributions in our database for this fund; it may not pay them, or history has not loaded yet.
Risk Statistics
Liquidity
| Volume today | 1.74K | Average volume | 2.10K |
| AUM | $11.2M | Premium/Discount | -2.19% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV: an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Week | $914.7K | +9.06% | $10.1M → $11.2M |
| 1 Month | $1.4M | +14.38% | $9.9M → $11.2M |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source; review them before investing.
Latest News for TDNA
No articles mention this fund directly in the last 7 days; showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.